Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial


Por: Vaz-Salgado, MA, Del Barco, S, Sepúlveda, JM, Alonso, M, Pineda, E, Balana, C, Martínez-García, M and Gironés, R

Publicada: 4 dic 2025 Ahead of Print: 4 dic 2025
Resumen:
The hedgehog pathway is implicated in resistance to anticancer therapies in glioblastoma (GB). GEINO1602 (NCT03466450) phase Ib/II study evaluated the safety and efficacy of glasdegib and the Stupp scheme in newly diagnosed GB. Patients received glasdegib with radiotherapy plus concomitant and 6 cycles of adjuvant temozolomide followed by glasdegib monotherapy. The recommended phase 2 dose was 75 mg/day of glasdegib. The primary endpoint was the 15-months overall survival (OS), with a futility threshold of 60% to consider the trial positive; accrual required 70 evaluable patients. 79 patients were enrolled. The 15 m OS rate was 52.1% (95% CI: 41.7-65.2). At 2 years, 29.2% of the patients were still alive. The median progression-free survival (PFS) was 7.1 months (95% CI: 6.2-8.6). Glasdegib plus chemoradiotherapy show preliminary efficacy. Despite not surpassing the futility threshold, 30% lived at the data cutoff. Translational research will help define the molecular traits of long-term survivors.

Filiaciones:
Vaz-Salgado, MA:
 Hosp Univ Ramon & Cajal, Inst Ramon & Cajal Invest Sanitaria Irycis, Med Oncol Dept, Biomarkers & Personalized Approach Canc Grp BioPAC, Madrid, Spain

Del Barco, S:
 Inst Catala Oncol Girona, Med Oncol Dept, Girona, Spain

Sepúlveda, JM:
 Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

Alonso, M:
 Hosp Virgen Rocio, Med Oncol Dept, Seville, Spain

Pineda, E:
 IDIBAPS, Med Oncol Dept Hosp Clin & Translat Genom & Target, Barcelona, Spain

:
 Inst Catala Oncol, Med Oncol Dept, Badalona, Spain

Martínez-García, M:
 Hosp del Mar, Med Oncol Dept, Barcelona, Spain

Gironés, R:
 Hosp Univ & Politecn La Fe, Med Oncol Dept, Valencia, Spain
ISSN: 20411723





Nature Communications
Editorial
Nature Publishing Group, HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY, Reino Unido
Tipo de documento: Article
Volumen: 17 Número: 1
Páginas: 86-86
WOS Id: 001654724500003
ID de PubMed: 41345097
imagen Green Submitted, gold

MÉTRICAS